| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.
|
Blood
|
2008
|
7.01
|
|
2
|
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.
|
Blood
|
2012
|
2.97
|
|
3
|
New treatment options have changed the survival of patients with follicular lymphoma.
|
J Clin Oncol
|
2005
|
2.40
|
|
4
|
Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains.
|
Hum Gene Ther
|
2007
|
2.23
|
|
5
|
High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis.
|
Blood
|
2003
|
2.17
|
|
6
|
Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.
|
Blood
|
2009
|
2.04
|
|
7
|
A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy.
|
Blood
|
2009
|
1.72
|
|
8
|
Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas.
|
Blood
|
2002
|
1.67
|
|
9
|
A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations.
|
Blood
|
2009
|
1.66
|
|
10
|
Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma.
|
Leuk Lymphoma
|
2008
|
1.63
|
|
11
|
Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab.
|
Blood
|
2008
|
1.58
|
|
12
|
Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma.
|
Oncologist
|
2008
|
1.52
|
|
13
|
131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission.
|
Blood
|
2005
|
1.48
|
|
14
|
Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.
|
J Immunol
|
2008
|
1.48
|
|
15
|
Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice.
|
Blood
|
2009
|
1.46
|
|
16
|
High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma.
|
Blood
|
2002
|
1.45
|
|
17
|
Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes.
|
Mol Ther
|
2004
|
1.36
|
|
18
|
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.
|
Blood
|
2005
|
1.33
|
|
19
|
High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.
|
J Clin Oncol
|
2007
|
1.31
|
|
20
|
Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.
|
J Nucl Med
|
2003
|
1.26
|
|
21
|
Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial.
|
J Clin Oncol
|
2013
|
1.23
|
|
22
|
Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older.
|
J Clin Oncol
|
2005
|
1.22
|
|
23
|
A biomimetic pH-responsive polymer directs endosomal release and intracellular delivery of an endocytosed antibody complex.
|
Bioconjug Chem
|
2002
|
1.19
|
|
24
|
Evidence mounts for the efficacy of radioimmunotherapy for B-cell lymphomas.
|
J Clin Oncol
|
2008
|
1.17
|
|
25
|
⁹⁰Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma.
|
Blood
|
2011
|
1.12
|
|
26
|
Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
1.11
|
|
27
|
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.
|
Haematologica
|
2012
|
1.09
|
|
28
|
A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies.
|
Cancer Res
|
2006
|
1.09
|
|
29
|
Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211.
|
Cancer Res
|
2009
|
1.08
|
|
30
|
A streptavidin-biotin binding system that minimizes blocking by endogenous biotin.
|
Bioconjug Chem
|
2002
|
1.03
|
|
31
|
Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas.
|
Blood
|
2006
|
1.03
|
|
32
|
Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy.
|
Blood
|
2007
|
1.03
|
|
33
|
Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium.
|
Leuk Lymphoma
|
2010
|
1.02
|
|
34
|
Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates.
|
Blood
|
2009
|
0.99
|
|
35
|
Anti-CD22 antibody targeting of pH-responsive micelles enhances small interfering RNA delivery and gene silencing in lymphoma cells.
|
Mol Ther
|
2011
|
0.97
|
|
36
|
Pretargeted radioimmunotherapy for B-cell lymphomas.
|
Clin Cancer Res
|
2007
|
0.97
|
|
37
|
Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas.
|
Cancer
|
2010
|
0.96
|
|
38
|
Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas.
|
Blood
|
2007
|
0.96
|
|
39
|
Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas.
|
Cancer Res
|
2007
|
0.96
|
|
40
|
High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience.
|
Cancer
|
2008
|
0.95
|
|
41
|
Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.
|
J Clin Oncol
|
2011
|
0.94
|
|
42
|
Targeted cancer therapy with a novel low-dose rate alpha-emitting radioimmunoconjugate.
|
Blood
|
2007
|
0.93
|
|
43
|
Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.
|
Blood
|
2010
|
0.93
|
|
44
|
Selection of first-line therapy for advanced follicular lymphoma.
|
J Clin Oncol
|
2013
|
0.92
|
|
45
|
Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis.
|
J Clin Oncol
|
2013
|
0.91
|
|
46
|
Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.
|
Cancer Res
|
2009
|
0.91
|
|
47
|
Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism.
|
Blood
|
2003
|
0.91
|
|
48
|
Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy.
|
Biol Blood Marrow Transplant
|
2006
|
0.90
|
|
49
|
High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes.
|
J Nucl Med
|
2004
|
0.90
|
|
50
|
Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation.
|
J Immunol
|
2010
|
0.89
|
|
51
|
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model.
|
Blood
|
2011
|
0.89
|
|
52
|
A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.
|
Cancer Res
|
2013
|
0.88
|
|
53
|
Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop.
|
Leuk Lymphoma
|
2010
|
0.87
|
|
54
|
A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era.
|
Br J Haematol
|
2014
|
0.86
|
|
55
|
Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas.
|
Clin Cancer Res
|
2005
|
0.86
|
|
56
|
R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433.
|
Br J Haematol
|
2014
|
0.86
|
|
57
|
Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants.
|
Bioconjug Chem
|
2010
|
0.86
|
|
58
|
Epidemiology, Diagnosis, and Treatment of HIV-Associated Non-Hodgkin Lymphoma in Resource-Limited Settings.
|
Adv Hematol
|
2012
|
0.86
|
|
59
|
Pretargeted radioimmunotherapy for hematologic and other malignancies.
|
Cancer Biother Radiopharm
|
2010
|
0.86
|
|
60
|
Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose.
|
J Nucl Med
|
2008
|
0.86
|
|
61
|
Intracellular delivery and trafficking dynamics of a lymphoma-targeting antibody-polymer conjugate.
|
Mol Pharm
|
2012
|
0.86
|
|
62
|
Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133.
|
J Clin Oncol
|
2003
|
0.86
|
|
63
|
A pretargeted nanoparticle system for tumor cell labeling.
|
Mol Biosyst
|
2010
|
0.85
|
|
64
|
Treatment of lymphoma with adoptively transferred T cells.
|
Expert Opin Biol Ther
|
2009
|
0.85
|
|
65
|
Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438).
|
Blood
|
2008
|
0.84
|
|
66
|
Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2013
|
0.84
|
|
67
|
Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.
|
Clin Cancer Res
|
2011
|
0.84
|
|
68
|
Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate model.
|
Clin Cancer Res
|
2005
|
0.83
|
|
69
|
Advances in the treatment of hematologic malignancies using immunoconjugates.
|
Blood
|
2014
|
0.83
|
|
70
|
Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma.
|
Bioconjug Chem
|
2005
|
0.82
|
|
71
|
Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission.
|
J Nucl Med
|
2011
|
0.82
|
|
72
|
131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma.
|
Blood
|
2009
|
0.81
|
|
73
|
Reagents for astatination of biomolecules. 4. Comparison of maleimido-closo-decaborate(2-) and meta-[(211)At]astatobenzoate conjugates for labeling anti-CD45 antibodies with [(211)At]astatine.
|
Bioconjug Chem
|
2009
|
0.81
|
|
74
|
Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.
|
Blood
|
2013
|
0.81
|
|
75
|
A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma.
|
Br J Haematol
|
2013
|
0.79
|
|
76
|
Topical polyene antifungals in hematopoietic cell transplant patients: tolerability and efficacy.
|
Support Care Cancer
|
2004
|
0.78
|
|
77
|
Mantle cell lymphoma: report of the 2009 Mantle Cell Lymphoma Consortium Workshop.
|
Leuk Lymphoma
|
2010
|
0.78
|
|
78
|
Effect of cationic side-chains on intracellular delivery and cytotoxicity of pH sensitive polymer-doxorubicin nanocarriers.
|
Nanoscale
|
2012
|
0.78
|
|
79
|
The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation.
|
Leuk Lymphoma
|
2007
|
0.78
|
|
80
|
Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies.
|
Curr Opin Hematol
|
2007
|
0.77
|
|
81
|
Streptavidin in antibody pretargeting. 3. Comparison of biotin binding and tissue localization of 1,2-cyclohexanedione and succinic anhydride modified recombinant streptavidin.
|
Bioconjug Chem
|
2002
|
0.77
|
|
82
|
Depletion of Tregs for adoptive T-cell therapy using CD44 and CD137 as selection markers.
|
Immunotherapy
|
2012
|
0.76
|
|
83
|
131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes.
|
Nucl Med Commun
|
2012
|
0.76
|
|
84
|
Radioimmunotherapy consolidation and rituximab maintenance in the initial treatment of follicular lymphoma.
|
EJNMMI Res
|
2011
|
0.76
|
|
85
|
Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity.
|
Leuk Lymphoma
|
2014
|
0.75
|
|
86
|
Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation.
|
Anticancer Drugs
|
2015
|
0.75
|
|
87
|
Risk of non-Hodgkin lymphoma in relation to tricyclic antidepressant use.
|
Ann Epidemiol
|
2013
|
0.75
|
|
88
|
90Y-ibritumomab tiuxetan therapy in allogeneic transplantation in B-cell lymphoma with extensive marrow involvement and chronic lymphocytic leukemia: utility of pretransplantation biodistribution.
|
Nucl Med Commun
|
2014
|
0.75
|
|
89
|
Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies.
|
Cancer Biother Radiopharm
|
2008
|
0.75
|
|
90
|
Conditionally cleavable radioimmunoconjugates: a novel approach for the release of radioisotopes from radioimmunoconjugates.
|
Bioconjug Chem
|
2003
|
0.75
|
|
91
|
Recent advances in novel radioimmunotherapeutic approaches for allogeneic hematopoietic cell transplantation.
|
Curr Opin Oncol
|
2010
|
0.75
|